UBS O'Connor’s AbbVie ABBV Stock Holding History

UBS O'Connor’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$21.6K	–	511
2023 Q4	$21.6K	Buy	+10,000	New	+$1.46M	﹤0.01%	444

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS O'Connor's ABBV Position: Q3 2025 in Review

UBS O'Connor sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 13,297 shares — an estimated $2.47M sold.

UBS O'Connor first reported a position in ABBV in Q2 2015 and held it in 13 quarters. The position peaked at $5.6M in Q2 2023. 3,915 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

UBS O'Connor reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 13,297 AbbVie shares in Q3 2025, an estimated $2.47M.
UBS O'Connor first reported a position in AbbVie in Q2 2015 and held it in 13 quarters.
UBS O'Connor's AbbVie position peaked at $5.6M in Q2 2023.
3,915 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.